TY - JOUR
T1 - Glycemic excursions and subclinical cardiac damage in adults with type 2 diabetes
T2 - Results from the ADVANCE Trial
AU - Rooney, Mary R.
AU - Wang, Dan
AU - McEvoy, J. William
AU - Juraschek, Stephen P.
AU - Chalmers, John
AU - Woodward, Mark
AU - Selvin, Elizabeth
N1 - Funding Information:
The research reported was supported by NIH grants R01 DK108784 (to Dr. Selvin), T32 HL007024 (Rooney), and K24 HL152440 (Selvin).
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12
Y1 - 2021/12
N2 - We found that 1,5-anhydroglucitol—a marker of glucose excursions—was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.
AB - We found that 1,5-anhydroglucitol—a marker of glucose excursions—was not independently associated with subclinical cardiac damage, nor with vascular outcomes, in the ADVANCE Trial. High-sensitivity cardiac troponin T and N-terminal pro-b-type natriuretic peptide provided better prognostic information regarding vascular risk in diabetes than 1,5-anhydroglucitol.
UR - http://www.scopus.com/inward/record.url?scp=85119961998&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119961998&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2021.109148
DO - 10.1016/j.diabres.2021.109148
M3 - Article
C2 - 34800609
AN - SCOPUS:85119961998
SN - 0168-8227
VL - 182
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 109148
ER -